These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

226 related items for PubMed ID: 1884734

  • 1. Metabolism of paracetamol and phenacetin in relation to debrisoquine oxidation phenotype.
    Veronese ME, McLean S.
    Eur J Clin Pharmacol; 1991; 40(6):547-52. PubMed ID: 1884734
    [Abstract] [Full Text] [Related]

  • 2. The contribution of genetically determined oxidation status to inter-individual variation in phenacetin disposition.
    Devonshire HW, Kong I, Cooper M, Sloan TP, Idle JR, Smith RL.
    Br J Clin Pharmacol; 1983 Aug; 16(2):157-66. PubMed ID: 6615690
    [Abstract] [Full Text] [Related]

  • 3. Polymorphism of carbon oxidation of drugs and clinical implications.
    Sloan TP, Mahgoub A, Lancaster R, Idle JR, Smith RL.
    Br Med J; 1978 Sep 02; 2(6138):655-7. PubMed ID: 151576
    [Abstract] [Full Text] [Related]

  • 4. Animal modelling of human polymorphic drug oxidation--the metabolism of debrisoquine and phenacetin in rat inbred strains.
    Al-Dabbagh SG, Idle JR, Smith RL.
    J Pharm Pharmacol; 1981 Mar 02; 33(3):161-4. PubMed ID: 6116757
    [Abstract] [Full Text] [Related]

  • 5. Metabolic oxidation of methaqualone in extensive and poor metabolisers of debrisoquine.
    Oram M, Wilson K, Burnett D, Al-Dabbagh SG, Idle JR, Smith RL.
    Eur J Clin Pharmacol; 1982 Mar 02; 23(2):147-50. PubMed ID: 7140803
    [Abstract] [Full Text] [Related]

  • 6. Genetically determined oxidation capacity and the disposition of debrisoquine.
    Sloan TP, Lancaster R, Shah RR, Idle JR, Smith RL.
    Br J Clin Pharmacol; 1983 Apr 02; 15(4):443-50. PubMed ID: 6849780
    [Abstract] [Full Text] [Related]

  • 7. Lack of relationship between tolbutamide metabolism and debrisoquine oxidation phenotype.
    Peart GF, Boutagy J, Shenfield GM.
    Eur J Clin Pharmacol; 1987 Apr 02; 33(4):397-402. PubMed ID: 3443146
    [Abstract] [Full Text] [Related]

  • 8. Kinetics and metabolism of paracetamol and phenacetin.
    Prescott LF.
    Br J Clin Pharmacol; 1980 Oct 02; 10 Suppl 2(Suppl 2):291S-298S. PubMed ID: 7002186
    [Abstract] [Full Text] [Related]

  • 9. Formation of reactive metabolites of phenacetin in humans and rats.
    Veronese ME, McLean S, D'Souza CA, Davies NW.
    Xenobiotica; 1985 Nov 02; 15(11):929-40. PubMed ID: 4082633
    [Abstract] [Full Text] [Related]

  • 10. Metabolism of phenacetin and N-hydroxyphenacetin in isolated rat hepatocytes.
    McLean S.
    Naunyn Schmiedebergs Arch Pharmacol; 1978 Nov 02; 305(2):173-80. PubMed ID: 732893
    [Abstract] [Full Text] [Related]

  • 11. Polymorphic drug oxidation in humans.
    Eichelbaum M.
    Fed Proc; 1984 May 15; 43(8):2298-302. PubMed ID: 6714436
    [Abstract] [Full Text] [Related]

  • 12. Influence of DH/DL alleles regulating debrisoquine oxidation on phenytoin hydroxylation.
    Sloan TP, Idle JR, Smith RL.
    Clin Pharmacol Ther; 1981 Apr 15; 29(4):493-7. PubMed ID: 7471615
    [Abstract] [Full Text] [Related]

  • 13. Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine.
    Speirs CJ, Murray S, Boobis AR, Seddon CE, Davies DS.
    Br J Clin Pharmacol; 1986 Dec 15; 22(6):739-43. PubMed ID: 3567021
    [Abstract] [Full Text] [Related]

  • 14. Influence of debrisoquine hydroxylation phenotype on the pharmacokinetics of mexiletine.
    Lledó P, Abrams SM, Johnston A, Patel M, Pearson RM, Turner P.
    Eur J Clin Pharmacol; 1993 Dec 15; 44(1):63-7. PubMed ID: 8436157
    [Abstract] [Full Text] [Related]

  • 15. The metabolism of mexiletine in relation to the debrisoquine/sparteine-type polymorphism of drug oxidation.
    Broly F, Vandamme N, Libersa C, Lhermitte M.
    Br J Clin Pharmacol; 1991 Oct 15; 32(4):459-66. PubMed ID: 1958440
    [Abstract] [Full Text] [Related]

  • 16. The relationship between debrisoquine oxidation phenotype and the pharmacokinetics and pharmacodynamics of propranolol.
    Lennard MS, Jackson PR, Freestone S, Tucker GT, Ramsay LE, Woods HF.
    Br J Clin Pharmacol; 1984 Jun 15; 17(6):679-85. PubMed ID: 6743465
    [Abstract] [Full Text] [Related]

  • 17. Hepatotoxic metabolic activation of paracetamol and its derivatives phenacetin and benorilate: oxygenation or electron transfer?
    de Vries J.
    Biochem Pharmacol; 1981 Mar 01; 30(5):399-402. PubMed ID: 6112004
    [No Abstract] [Full Text] [Related]

  • 18. Comparative effects of the diastereoisomers, quinine and quinidine in producing phenocopy debrisoquine poor metabolisers (PMs) in healthy volunteers.
    Ayesh R, Dawling S, Hayler A, Oates NS, Cholerton S, Widdop B, Idle JR, Smith RL.
    Chirality; 1991 Mar 01; 3(1):14-8. PubMed ID: 2039678
    [Abstract] [Full Text] [Related]

  • 19. Effect of an experimental malaria infection on the metabolism of phenacetin in the rat isolated perfused liver.
    Glazier AP, Kokwaro GO, Ismail S, Edwards G.
    Xenobiotica; 1994 Aug 01; 24(8):785-93. PubMed ID: 7839701
    [Abstract] [Full Text] [Related]

  • 20. Lack of relationship between debrisoquine oxidation phenotype and the pharmacokinetics of quinine.
    Wanwimolruk S, Chalcroft S.
    Br J Clin Pharmacol; 1991 Nov 01; 32(5):617-20. PubMed ID: 1954076
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.